Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Inhibiting PI3Kβ with AZD8186 regulates key metabolic pathways in PTEN-null tumours.

Lynch J, Polanska UM, Delpuech O, Hancox U, Garcia-Trinidad A, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling JE, Staniszewska AD, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res. 2017 Oct 2. pii: clincanres.0676.2017. doi: 10.1158/1078-0432.CCR-17-0676. [Epub ahead of print]

PMID:
28972046
2.

Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.

Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, Calvo V, Cheung JF, Bravo-Cordero JJ, Entenberg D, Castracane J, Verkhusha V, Keely PJ, Condeelis J, Aguirre-Ghiso JA.

Nat Cell Biol. 2017 Feb;19(2):120-132. doi: 10.1038/ncb3465. Epub 2017 Jan 23.

3.

Mechanism of early dissemination and metastasis in Her2+ mammary cancer.

Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girnius N, Davis RJ, Farias EF, Condeelis J, Klein CA, Aguirre-Ghiso JA.

Nature. 2016 Dec 14. doi: 10.1038/nature20609. [Epub ahead of print]

PMID:
27974798
4.

Validation of a device for the active manipulation of the tumor microenvironment during intravital imaging.

Williams JK, Entenberg D, Wang Y, Avivar-Valderas A, Padgen M, Clark A, Aguirre-Ghiso JA, Castracane J, Condeelis JS.

Intravital. 2016;5(2). pii: e1182271. Epub 2016 Apr 29.

5.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Hudson K, Hancox UJ, Trigwell C, McEwen R, Polanska UM, Nikolaou M, Morentin Gutierrez P, Avivar-Valderas A, Delpuech O, Dudley P, Hanson L, Ellston R, Jones A, Cumberbatch M, Cosulich SC, Ward L, Cruzalegui F, Green S.

Mol Cancer Ther. 2016 May;15(5):877-89. doi: 10.1158/1535-7163.MCT-15-0687. Epub 2016 Feb 2.

6.

Epithelial Xbp1 is required for cellular proliferation and differentiation during mammary gland development.

Hasegawa D, Calvo V, Avivar-Valderas A, Lade A, Chou HI, Lee YA, Farias EF, Aguirre-Ghiso JA, Friedman SL.

Mol Cell Biol. 2015 May;35(9):1543-56. doi: 10.1128/MCB.00136-15. Epub 2015 Feb 23.

7.

Stress signaling and the shaping of the mammary tissue in development and cancer.

Avivar-Valderas A, Wen HC, Aguirre-Ghiso JA.

Oncogene. 2014 Nov 27;33(48):5483-90. doi: 10.1038/onc.2013.554. Epub 2014 Jan 13. Review.

8.

A human tRNA methyltransferase 9-like protein prevents tumour growth by regulating LIN9 and HIF1-α.

Begley U, Sosa MS, Avivar-Valderas A, Patil A, Endres L, Estrada Y, Chan CT, Su D, Dedon PC, Aguirre-Ghiso JA, Begley T.

EMBO Mol Med. 2013 Mar;5(3):366-83. doi: 10.1002/emmm.201201161. Epub 2013 Feb 4.

9.

Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK.

Avivar-Valderas A, Bobrovnikova-Marjon E, Alan Diehl J, Bardeesy N, Debnath J, Aguirre-Ghiso JA.

Oncogene. 2013 Oct 10;32(41):4932-40. doi: 10.1038/onc.2012.512. Epub 2012 Nov 19.

10.

Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer.

Kim RS, Avivar-Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre-Ghiso JA, Segall JE.

PLoS One. 2012;7(4):e35569. doi: 10.1371/journal.pone.0035569. Epub 2012 Apr 18.

11.

Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties.

Bragado P, Estrada Y, Sosa MS, Avivar-Valderas A, Cannan D, Genden E, Teng M, Ranganathan AC, Wen HC, Kapoor A, Bernstein E, Aguirre-Ghiso JA.

PLoS One. 2012;7(1):e29974. doi: 10.1371/journal.pone.0029974. Epub 2012 Jan 20.

12.

Transcriptional repression of the tumor suppressor DRO1 by AIB1.

Ferragud J, Avivar-Valderas A, Pla A, De Las Rivas J, Font de Mora J.

FEBS Lett. 2011 Oct 3;585(19):3041-6. doi: 10.1016/j.febslet.2011.08.025. Epub 2011 Aug 25.

13.

PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment.

Avivar-Valderas A, Salas E, Bobrovnikova-Marjon E, Diehl JA, Nagi C, Debnath J, Aguirre-Ghiso JA.

Mol Cell Biol. 2011 Sep;31(17):3616-29. doi: 10.1128/MCB.05164-11. Epub 2011 Jun 27.

14.

ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA.

Clin Cancer Res. 2011 Sep 15;17(18):5850-7. doi: 10.1158/1078-0432.CCR-10-2574. Epub 2011 Jun 14. Review.

15.

p38α Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis.

Wen HC, Avivar-Valderas A, Sosa MS, Girnius N, Farias EF, Davis RJ, Aguirre-Ghiso JA.

Sci Signal. 2011 May 24;4(174):ra34. doi: 10.1126/scisignal.2001684.

16.

Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis.

Sequeira SJ, Wen HC, Avivar-Valderas A, Farias EF, Aguirre-Ghiso JA.

BMC Cell Biol. 2009 Sep 15;10:64. doi: 10.1186/1471-2121-10-64.

Supplemental Content

Loading ...
Support Center